Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?

Impact · against what's priced in

The article provides no new catalysts for Revolution Medicines, as the FDA approval, survival data, and pricing for Rasonque are already factored into the current stock price. The mention of Stanley Druckenmiller's stake increase is also a known historical event that does not change the current valuation thesis.

RVMD+0.00

Already priced in

The price assumes

FDA approval and commercial launch of daraxonrasib (RASONQUE)